

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/46, C12N 9/96, A61K 9/12	A1	(11) International Publication Number: WO 95/23613 (43) International Publication Date: 8 September 1995 (08.09.95)
(21) International Application Number: PCT/US95/02041 (22) International Filing Date: 28 February 1995 (28.02.95) (30) Priority Data: 08/206,020 4 March 1994 (04.03.94) US 08/364,074 27 December 1994 (27.12.94) US (71) Applicant: GENENTECH, INC. [US/US]; 460 Point San Bruno Boulevard, South San Francisco, CA 94080 (US). (72) Inventors: CHAN, Hak-Kim; 1536 Jasmine Street, San Mateo, CA 94402 (US). CLARK, Andrew, R.; 436 Valdez Avenue, Half Moon Bay, CA 94019 (US). GONDA, Igor; 2351 Larkin Street, San Francisco, CA 94109 (US). HSU, Chung, S.; 13120 Delson Court, Los Altos Hills, CA 94022 (US). MUMENTHALER, Marco; Im Schänzli 107, CH-4132 Muttrenz (CH). SHIRE, Steven, J.; 2417 Lincoln Avenue, Belmont, CA 94002 (US). (74) Agents: DREGER, Walter, H. et al.; Flehr, Hohbach, Test, Albritton & Herbert, Suite 3400, 4 Embarcadero Center, San Francisco, CA 94111-4187 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION (57) Abstract The present invention describes methods and means for preparing pharmaceutically acceptable formulations of DNase via spray-drying solutions comprising said DNase and a compatible excipient under conditions such that a dry powder containing DNase is produced. Such products of spray drying result in the exhibition of properties known to be essential for therapeutic effectiveness when the formulations are administered by dispersion into the lung of an individual patient. The therapeutic effect results in the DNase effecting enzymatic alteration of the viscoelasticity of mucus within the lung of the individual so treated.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION**Cross-Reference to Related Applications**

The present application is related in subject matter to the disclosure contained in U.S. patent application Serial
5 No. 07/448,038, filed 8 December 1989, and in U.S. patent application Serial No. 07/289,958, filed 23 December 1988, and in U.S. patent application Serial No. 07/895,300, filed 8 June 1992. The content of these prior applications is hereby expressly incorporated by reference
10 herein.

Field of the Invention

The present invention is related to results obtained from research on the formulation of deoxyribonuclease, otherwise referred to as DNase, a phosphodiesterase that
15 is capable of hydrolyzing polydeoxyribonucleic acid (DNA).

The present invention relates generally to the preparation of pharmaceutically acceptable formulations comprising DNase in therapeutically effective form for administration into the lung of an individual. It relates to these
20 formulations per se and to their use clinically and to methods of preparing and using such DNase formulations.

Background of the Invention

DNase is a phosphodiesterase capable of hydrolyzing polydeoxyribonucleic acid. DNase has been purified from various species to various degrees. The complete amino acid sequence for a mammalian DNase was first made available in 1973. See, e.g., Liao, et al., J. Bio. Chem. 248, 1489 (1973).

DNase has a number of known utilities and has been used for therapeutic purposes. Its principal therapeutic use has been to reduce the viscoelasticity of pulmonary secretions in such diseases as pneumonia and cystic fibrosis, thereby aiding in the clearing of respiratory airways. See, e.g., Lourenco, et al., Arch. Intern. Med. 142, 2299 (1982); Shak, et al., Proc. Nat. Acad. Sci. 87, 9188 (1990); and Hubbard, et al., New England Journal of Medicine 326, 812 (1992).

DNA encoding human DNase has been isolated and sequenced and that DNA has been expressed in recombinant mammalian host cells, thereby enabling the production of human DNase in commercially useful quantities. See, e.g., Shak, et al., Proc. Nat. Acad. Sci. 87, 9188 (1990). Recombinant human DNase (rhDNase) has been found to be useful clinically, especially in purified form such that the DNase is free from proteases and other proteins with which it is ordinarily associated in nature.

The means and methods by which human DNase can be obtained in pharmaceutically effective form is described in the patent applications cited above. Various specific methods for the purification of DNase are known in the art. See, e.g., Khouw, et al., U.S. Patent No. 4,065,355, issued 27 December 1977; Markey, FEBS Letters 167, 155 (1984); and Nefsky, et al., Euro. Journ. Biochem. 179, 215 (1989).

-3-

The present application is predicated on the use of such DNase for formulation. DNase can be employed as such, as a mixture of deamidated and non-deamidated forms, or in isolated deamidated and non-deamidated forms,

- 5 non-deamidated human DNase being regarded as the more active species. The preparation and separation of such forms are the subject matter of the patent application cited above.

- The present invention is directed to the formulation of
10 DNase (including all of its biologically active forms as previously noted) such that the biologically active species can be administered directly into the lung for therapeutic effect.

- Because DNase exhibits its therapeutic effect in the lungs
15 of an individual, it is essential that the DNase be deposited in the respiratory tract in a therapeutically active form. Thus, it is important that formulations of DNase contain such DNase in substantially biologically active form, and in order to assure administration
20 effectively, it is important that the DNase be formulated such that, when inhaled, it will be delivered in biologically active form preferably into the lung of the individual being treated.

- Initially, the DNase was subjected to more or less
25 standard lyophilization techniques in order to produce a dry powdered form that could be inhaled. The process of lyophilization is difficult to manage in order to consistently produce powders that exhibit properties satisfying the requirements of proper administration for
30 therapeutic effect: dispersibility, uniform particle size, non-aggregated forms, biologically active drug principle.

Generally, spray-drying techniques have found a relatively wide range of applications within the chemical industry,

the food industry and the biochemical and pharmaceutical industries. See, e.g., Drug Development and Industrial Pharmacy 18 (11 and 12), 1169-1206 (1992), entitled "The Spray Drying of Pharmaceuticals" and, generally, U.S. Patent No. 4,233,405.

Spray drying is becoming recognized as a method for the processing of materials; it has been used for pharmaceuticals such as antibiotics, and especially food products. The spray drying of pharmaceutical proteins is a new area of interest, and accordingly, has not been exploited commercially.

A number of problems attend the process of spray drying which could result in a product that does not have the required therapeutic characteristics as outlined above.

For example, Mumenthaler, et al. presented a feasibility study at the Sixth Annual AAPS Meeting in Washington, D. C. in November of 1991; that study was subsequently published in Pharmaceutical Research 11, 12 (1994). This feasibility study reported on endeavors to spray dry two protein pharmaceuticals: recombinant human growth hormone and recombinant tissue-type plasminogen activator. That study emphasized that the application of spray drying to therapeutic proteins is rather unexplored undoubtedly because of the concern that proteins may be thermally degraded during the operation, and hence, not suitably biologically active for therapeutic use. In this report, a number of publications are cited that would serve to confirm that prejudice in the art.

In the study, it was reported that although human growth hormone could be dried to a residual moisture content of about or less than 4%, approximately upwards of 25% of the protein was degraded during the processing resulting in a product that could not be exploited commercially for requisite therapeutic effect.

-5-

Contrary to what was found for human growth hormone, spray drying proved feasible with tissue plasminogen activator, emphasizing that unappreciated differences in molecular structure, and other factors influence the sensitivity of
5 . proteins to the phenomena essential for producing a therapeutically useful formulation by this means.

Thus, for inhalation or administration by inhalation into the lungs, these mixed results emphasize that it is not predictable that one could achieve success in producing a
10 therapeutically acceptable formulation of a given biologically active protein in this manner. Further, the additional requirements needed for administration of proteins by therapeutic inhalation introduces further uncertainty.

15 The effect of excipients and of thermal stability are matters that complicate prediction as to therapeutic success. Indeed, commercial enterprises have been established to conduct further research on this means of producing therapeutic formulations.

20 Summary of the Invention

The present invention is predicated on the finding that DNase together with a number of compatible excipients can be formulated via spray drying to produce a dispersion of dry powder containing the DNase as active drug principle
25 in biologically active form, having the physical characteristics such that the formulation is suitable for administration into the lung of an individual for consequential therapeutic effect.

The present invention is thus directed to a method for the
30 preparation of a pharmaceutically acceptable formulation comprising DNase which comprises the steps of spray drying a liquid composition comprising compatible excipients and DNase as active drug principle and collecting the

-6-

spray-dried product of such a step as a dispersible powder containing DNase in biologically active form.

The present invention is directed as well to the therapeutically effective DNase formulation resulting as a product of the process for its preparation herein.

The present invention is directed to such formulations, and their preparation, including the step of administering them into the lung of an individual, as well as all associated embodiments thereof relating to the preparation of formulations and their use therapeutically.

The present invention is more particularly directed to the preparation of pharmaceutically acceptable formulations comprising DNase as a powder to be used in an aerosol form, that is, a suspension of finely divided solid particles or solid particles in liquid droplets, suspended in a gas, that have proper dispersibility and particle size properties, preferably in substantially non-aggregated form, such that when administered into the lung of an individual they will be in a form likely to exhibit a therapeutic effect therein by the biologically active DNase drug principle.

The present invention is directed to the preparation of such formulations via a spray-drying technique having general parameters that when combined are useful for preparing the therapeutically active formulation. In particular, DNase powders can be produced in formulations in which less than about 4% of the active DNase principle is in aggregated form. The denaturation temperature of DNase is about 50 - 75°C depending on the medium. Thus, it is preferable to use inlet temperatures for the spray-drying process that do not exceed that temperature range by a great deal.

-7-

Similarly, the outlet temperature is an important consideration in respect of the denaturation temperature of DNase. It was determined that an outlet temperature in the spray-drying process as low as possible consistent
5 with drying the product is preferable, if not optimal. Generally, an outlet temperature of from about ambient to 75°C is employed, and more preferably, from about ambient to 70°C.

In respect of pH of the solution that is subjected to
10 spray drying, a range of from about 5 to 8 is probably optimal to avoid excessive aggregation and deamidation. It was found that ranges of pH of about 6 to 7 are preferred.

The spray-drying process employs initially a solution
15 containing DNase. Such solutions preferably are aqueous and will contain one or a number of pharmaceutically compatible excipients. Concentrations of DNase are from about 1 to about 80 or more milligrams per milliliter, more preferably 5 to 30 milligrams per milliliter.

20 While a wide range of pharmaceutically acceptable excipients are available and could be used in producing solutions that are preferable for the spray-drying process herein, it was found that the characteristics of the excipient are important but not (necessarily) essential
25 for producing a proper dispersible end product. In general, it has been found that suitable excipients are selected from the group consisting of sodium chloride, sugars (sucrose, lactose, trehalose and mannitol, for example), derived calcium or other divalent cations (such
30 as can be obtained from calcium chloride, zinc chloride, manganese chloride and magnesium chloride to name a number of examples). The mass concentration in conjunction with droplet size controls the particle size. It has been found, for example, that increasing the amount of salt
35 increases the dispersibility qualities of the spray-dried

-8-

product. In the case of sugars, increasing their proportion over about 30% lowers dispersibility qualities.

The spray-drying process hereof can be used suitably with any of a number of devices that are available in the art
5 and commercially.

The product powders hereof can be blended with additional known, dry excipients via usual procedures to produce blends thus tailored for various applications.

Brief Description of the Drawings

10 Figure 1 shows a scanning electron micrograph of rhDNase particles prepared as described in Example 1 hereof.

Figures 2A and 2B show two views of the Rotahaler® given as an example of a device used to redisperse the rhDNase powders.

15 Figure 3 is the multistage liquid impinger with the Rotahaler connected to the throat of the impinger for aerosol sizing of the rhDNase powders.

Figures 4 to 7 are comparisons of the particle size distribution of the raw powders to that in the aerosol
20 cloud generated by the Rotahaler for four formulations containing different NaCl contents.

Figure 8 is a summary of the redispersibility versus particle size for rhDNase powders containing NaCl.

Figures 9A and 9B show two representations of the
25 relationship between the primary particle size and the powder's redispersibility into respirable aerosol particles for a type of polydisperse powder (e.g., geometric standard deviation ~ 2.5).

RECTIFIED SHEET (RULE 91)
ISA/EP

-9-

Figure 10 shows the effect of NaCl content on the redispersion of the rhDNase powders.

Figure 11 shows a linear relationship between the NaCl content in the formulations and their crystallinity.

- 5 Figures 12A-12F show scanning electron micrographs of rhDNase particles containing NaCl.

- Figure 13 is a comparison of the particle size distribution of the raw powder and the aerosol clouds generated by the Rotahaler for the rhDNase powder
10 formulated with 40% lactose.

Figure 14 shows the redispersibility of rhDNase powders containing different sugar versus their sugar content.

Figure 15 shows the effect of particle size on the redispersibility of rhDNase powders formulated with sugar.

- 15 Figures 16A-16F show scanning electron micrographs of rhDNase particles containing sugars (16A,B,C: 40% sugar, 16D,E,F: 84% sugar; 16A,D: sucrose, 16B,E: lactose, and 16C,F: trehalose).

- Figure 17 shows an isoelectric focusing gel for DNase-
20 containing formulations. Lanes 1 and 4 are the DNase-salt formulation, lanes 2 and 5 are the DNase-lactose formulation and lanes 3 and 6 are the pure DNase formulation.

Detailed Description of the Invention

25 A. Definitions

By the term "DNase" or "human DNase" or "recombinant human DNase" herein is meant a polypeptide having the amino acid sequence of human mature DNase as well as amino acid

RECTIFIED SHEET (RULE 91)
ISA/EP

-9A-

sequence variants thereof (including allelic variants)
that are enzymatically active in hydrolyzing DNA. Thus,
the terms herein denote a broad definition of those

-10-

materials disclosed and prepared in the various patent applications cited above and incorporated herein by reference. It will be understood that the terms include both purified mixtures of deamidated and non-deamidated human DNase as well as purified forms of each.

By the term "excipient" herein is meant a pharmaceutically acceptable material that is employed together with DNase for the proper and successful preparation of a spray-dried formulation that results in therapeutic effect when administered into the lung of an individual patient. Suitable excipients are well-known in the art, and are generally described above and, for example, in the Physician's Desk Reference, the Merck Index and Remington's Pharmaceutical Sciences.

By the term "therapeutically effective" and grammatical equivalents thereof herein is meant dosages of from about 1 microgram to about 1 milligram of human DNase per kilogram of body weight of the individual being treated, administered within the spray-dried pharmaceutical formulations hereof. The current daily therapeutic dose of DNase is about 2.5 mg. The therapeutically effective amount of human DNase will depend, for example, upon the therapeutic objectives and the condition of the individual being treated. In all of that, the present invention provides as an essential component, spray-dried formulations containing therapeutically effective amounts, the formulations being prepared such that they suitably provide such therapeutic effect when administered into the lung of the individual.

The term "aerosol" herein refers to the use of the term in a pharmaceutical sense, and covers formulations that are comprised of a suspension of fine solid particles in air or solid particles in liquid droplets or droplets of solution in air. The term includes substances dispensed from a container as an aerosol, particularly for

-11-

- administration of the contents into the lung of an individual by inhalation and covers the container for this act as well. The aerosols hereof are comprised of dispersed solid particles with a particle size suitable for introduction into the lung. The particles should be approximately 1 to 6 microns in size of substantially non-aggregated biologically active DNase molecules for achieving therapeutic effect into the lung of the individual being treated.
- 10 The DNase formulations hereof are employed for enzymatic alteration of the viscoelasticity of mucus within the lung. Such formulations are particularly useful for the treatment of patients with pulmonary disease who have abnormal viscous, purulent secretions and conditions such as acute or chronic bronchial pulmonary disease, including infectious pneumonia, bronchitis or tracheobronchitis, bronchiectasis, cystic fibrosis, asthma, tuberculosis and fungal infections and the like. For such therapies, the novel formulations hereof are instilled in otherwise conventional fashion into the bronchi of the individual being treated. The formulations hereof are particularly suited for the assured introduction into the lung of DNase such that a therapeutically effective amount of DNase is delivered to the individual by direct action in the lung.

25 B. Preferred Embodiments

Introduction

- Dry powders of DNase were prepared for aerosol delivery. The powders were obtained by the method of spray drying; up to 4% of molecular aggregates were found in the powders. The presence of aggregates, in view of their potential for unwanted effects such as toxicity and immunogenicity, is preferably minimized. It is unlikely that the aggregation was due to the mechanical shearing stress during the process of spraying since DNase was not

-12-

denatured during jet nebulization. It may be therefore related to the drying process during which the spray droplets were exposed to air at elevated temperature. In fact, previous experiments show that during ultrasonic
5 nebulization, formation of DNase aggregates occurs due to thermal denaturation.

C. Examples

Example 1

An initial feasibility study designed to determine
10 the particle size distribution and quality of the rhDNase after spray drying was undertaken using rhDNase at 4 mg/mL formulated in 150 mM NaCl and 1 mM CaCl₂ at pH6.6. The spray drying was performed using a laboratory scale spray-dryer (Büchi, Model 190). During operation, protein
15 solution was fed at a constant rate of 5 mL/min with a peristaltic pump to a nozzle (0.5-mm I.D.), where atomization occurred by means of a pressurized air stream. Drying air entered the drying chamber at 90 °C and 36000L/hr (STP condition) in the same direction as the
20 descending spray droplets. In order to avoid the aspiration of dust particles from the laboratory atmosphere, drying air and atomization air were prefiltered with 70- and 0.22- μ m filters, respectively. The product powders were clarified from the drying-air
25 stream by means of a cyclone and collected in a receiving vessel.

The resulting fine white spray dried powder was assayed for moisture content by thermal gravimetric analysis and particle size and morphology were determined by electron
30 microscopy. The spray dried rhDNase powder (0.13 g) was also dissolved into 10 mL of milli-Q water, and the following assays were used to assess the quality of the redissolved rhDNase.

-13-

- color and clarity; to determine visual appearance of the solution.
- pH of reconstituted solution.
- UV spectrophotometric scan: to determine rhDNase
5 concentration using an absorptivity of $1.6 \text{ (mg/mL)}^{-1} \text{ cm}^{-1}$.
- Gel sizing chromatography: to determine the presence of molecular aggregates and fragments of rhDNase.
- Atomic absorption flame photometry: to determine Na^+ content.
- 10 - Isoelectric focusing (IEF): to determine charge distribution of rhDNase.
- SDS polyacrylamide gel electrophoresis (SDS PAGE): to determine presence of covalent aggregates and fragments of rhDNase.
- 15 - Methyl green DNA activity assay: to determine activity of rhDNase.

Results: The spray dried powders were found to contain approximately 30% rhDNase, 60% NaCl and 5% water. The molar ratio of sodium to protein in solution was
20 maintained in the spray dried powder (Table A). The charge distribution of rhDNase was unaltered after spray drying as determined by IEF. The pH and color and appearance of the redissolved spray dried powder was essentially unchanged (there were a few particles observed
25 in the clear reconstituted solutions). Gel sizing chromatography did show a slight decrease in the percent of monomer which was attributed to formation of aggregates. Some of the aggregates that are generated are due to intramolecular disulfide cross-linking shown by the
30 presence of reducible high molecular weight bands detected by SDS PAGE. Most importantly the specific activity of the rhDNase after spray drying was unaltered (Table A). Electron microscopy of the spray dried powder showed spherical particles with a size range that suggests if
35 dispersed properly and inhaled, these particles would

-14-

likely be deposited in the broncho-tracheal region of the lungs (Figure A).

Table A: Stability of rhdNase to Spray Drying

Sample	Color and Appearance *	pH	† Concentration (mg/mL)	% Aggregate ‡	+ Activity (mg/mL)	Specific Activity **	[Na+]/ [rhdNase]
Before drying	co/cl	6.60	4.01	0.4	4.1±0.08	1.00±0.02	1235±27
After drying	co/po	6.64	3.40	3.3	3.51±0.06	1.03±0.02	1268±11

*: co=colorless, cl=clear, po=clear with occasional particulate.

†: concentration determined by UV spectroscopy

‡: % aggregate determined by gel sizing chromatography

+: activity determined by methyl green DNA activity assay and expressed as an active concentration

**: specific activity expressed as active concentration divided by concentration determined by UV spectroscopy.

-16-

Example 2Materials and Methods

rhDNase powders were prepared from a stock solution containing 4.7 mg/ml rhDNase, 1mM CaCl₂ and 150 mM NaCl.

5 The stock solution was diafiltered to between 90 and 100 mg/ml rhDNase without water replenishment. Predetermined amounts of water and NaCl were added to the concentrated stock solution to prepare rhDNase solutions with a range of NaCl concentrations. For the sugar formulations, the

10 solution was first dialyzed in highly purified water to remove excess NaCl and CaCl₂, then concentrated by diafiltration, followed by adjustment to the desired concentration of rhDNase and sugars. Details of the rhDNase and excipient contents in the powders are

15 presented in Tables 1 and 2.

Table 1. Content of Spray Dried Powders of rhDNase with NaCl

DNase% ¹	Water% ²	NaCl% ³	Total%	Monomer% ⁴	Activity% ⁵
10.46	1.3	87.6	99.4	96.5	ND
35.3	4.5	59.9	99.7	98.2	114 ^a
47.6	5.5	45.2	98.3	99.5	ND
68.1	4.6	27.2	99.9	99.7	ND
82.2	10.1	8.00	100.1	99.5	105 ^b

Notes:

1. rhDNase content determined by UV absorption at 280 nm using an absorptivity of 1.6 (mg/ml)⁻¹cm⁻¹.
2. Water content determined by thermogravimetry.
- 20 3. NaCl content determined by flame photometry.
4. Monomer % was determined by size exclusion chromatography.

-17-

5. Activity was determined by the methyl green assay normalized to the protein concentration measured by UV absorption. ND: not determined.

a: $114 \pm 2\%$, number of determination = 8.

- 5 b: The mean of two determined values of 109.8 and 100.7%.

Table 2. Actual Content of Spray Dried Powders of rhDNase with Sugars

Excipient	DNase%	Water% ¹	Sugar % ²
Sucrose	11.2	6.62	82.2
	36.9	5.97	57.1
	70.5	6.08	23.4
Lactose	10.9	6.93	82.2
	35.4	6.24	58.4
	64.1	8.16	27.7
	85.8	5.98	8.2
Trehalose	11.2	7.48	81.3
	35.4	7.64	57.0
	68.1	8.10	23.8

Notes:

1. At similar excipient weight proportion of approximately 30%, the sugar powders gave 1 to 3%
10 higher moisture content than the NaCl powders.

2. Sugar content determined by weight difference.

Moisture content was determined thermogravimetrically (TGA 7, Perkin Elmer). Crystallinity of the powders was measured by X-ray powder diffraction. Particle morphology was observed under a scanning electron microscope (SEM) (525M, Philips).

-18-

Spray Drying of rhDNase

Spray drying was carried out on a Büchi 190 Mini Spray Dryer using filtered and/or dehumidified air. In order to minimize possible thermal degradation of the products, the cyclone and collection vessel were cooled. The rhDNase solutions were delivered at a rate of 5 ml/min. The inlet and outlet air temperatures were 90 and 55°C, respectively.

Results and Discussion

10 Spray Dried Powders of rhDNase With Sodium Chloride

Figures 4-7 compare the particle size distribution of the original powder (as determined by laser diffraction) to that in the aerosol clouds generated by the Rotahaler (as determined by the multiple stage liquid impinger) for four formulations containing different salt contents. For the raw powders, the diameters were obtained assuming unit density. Correction using the measured density of 1.3 would slightly shift the curve upward but the effect is minimal since the aerodynamic diameter of a particle is proportional to the square root of its density. The data indicate that the aerosols were not sufficiently redispersed to recover the size distribution of the original particles. This is common for most powder inhalers and is a result of the powder cohesiveness and the dispersing efficiency of the device (Rotahaler).

A summary of the redispersion as a function of the particle size and the NaCl (or rhDNase) content is presented in Figure 8. The extrapolated dash lines indicate the expected trend for the behavior of the powders.

RECTIFIED SHEET (RULE 91)
ISA/EP

-19-

Effect of Particle Size

The expected relationship between the primary particle size and the redispersibility into respirable aerosol particles is illustrated in Figures 9A and 9B. Generally, the finer the particles the more cohesive they are, which would lead to poor redispersibility. As the particles become bigger, they are better dispersed due to a decrease in cohesiveness. On further increase in particle size, the redispersibility would reach a maximum and decrease again due to a decrease in the number of fine particles. The 8% NaCl formulation follows this behavior (Figure 8). It shows that the redispersibility improves from 4 to 10% as the mean particle size increases from 2 to 5.8 μm .

Effect of the Excipient Content

The effect of NaCl content on the redispersion of the rhDNase powders is illustrated in Figure 10. The formulations all have similar particle size distributions with median diameters of 2.7 - 3.3 μm (span from laser diffraction 1.04 - 1.63). A linear plot was found: the higher the salt content, the better the redispersion.

Effect of Crystallinity And Total Water Content

Crystallinity is a measure of the presence of crystalline matter in the powders. In Figure 11, a linear relationship was obtained between the NaCl content in the formulations and their crystallinity. Consequently, there is a correlation between the powder redispersibility and crystallinity. The relationship between the total water content (Table 1) and redispersibility is not linear, suggesting a possible influence from other physicochemical variables (e.g., the surface adsorbed moisture component rather than the total water content).

RECTIFIED SHEET (RULE 91)
ISA/EP

-20-

Effect of Particle Morphology

Figures 12A-12F show that as the NaCl content increased, the morphology changed from spheres with very smooth surface textures, to spheres with surfaces having numerous cubic salt crystals, to faceted spheres and finally to spheres of agglomerated salt crystals. A series of morphological features was thus observed. The macroscopic shape is not important since the faceted and smooth spheres were quite similar, yet their redispersions were very different.

Spray Dried Powders of rhDNase with Sugars

Figure 13 compares, as an example, the particle size distribution of the original powder and the aerosol clouds generated by the Rotahaler for rhDNase powders formulated with 40% lactose. As in the NaCl formulations, it indicates that the size distribution of the original particles is not recovered in the aerosol.

Effect of Types of Sugars

In Figure 14, rhDNase particles containing lactose were better dispersed than those containing sucrose or trehalose. The highest redispersibility was >40% which is quite comparable to those of the salt formulations. For a given sugar, the redispersibility decreases with increasing sugar content. As the sugar content increased, however, the particle size also increased (the higher sugar % gave larger median size, even though the total solute content in the spraying solutions had been kept at the same initial level). Thus, the change in the powder performance is also partly due to the change of particle size. This is very different from the behavior of the NaCl formulations.

-21-

For a given sugar, the redispersibility declines from a median particle size of around 2 μm , indicating that the maximum occurs at particle size $\leq 2 \mu\text{m}$ (Figure 15). Usually fine particles are quite sticky and therefore not dispersed well (Figures 9A and 9B). Fine sugar particles disperse quite well.

Effect of Crystallinity, Water Content and Particle Morphology

Unlike the NaCl powders which showed distinctive crystallinity due to the salt, none of the sugar powders were crystalline as measured by X-ray powder diffraction. The broad hump observed for the sugar powders is a typical feature of amorphous materials. Therefore, the redispersibility of the sugar powders is not related to crystallinity.

There was no systematic change in redispersibility with water content (Table 2). For a given sugar, the difference in the water content of the powders with different sugar content was only 1 to 2%. The same small difference in moisture was obtained for the three different sugars at similar sugar concentration. Moisture sorption isotherms indicate that crystallization of the Dnase powders occurs at relatively high humidity (about 70% to 85% or more), making it desirable to manufacture and store the powders under conditions of relatively low humidity.

When examined by the SEM, all the sugar formulated rhDNase powders looked alike with very smooth surface textures (Figures 16A-16F) which is also in sharp contrast to the NaCl particles. However, when the sugar content was very high, i.e. 90%, the particle morphology looked really irregular and the size was very large (Figures 16D-F), both of these features explained the much lower redispersibility of these powders. The integrity of the formulations is evidenced by the IEF results in Figure 17.

RECTIFIED SHEET (RULE 91)
ISA/EP

-22-

Study on Mannitol

Mannitol was attempted at 30% content only. Like other powders, the particles were smooth spheres under SEM. The powder, however, also showed distinct behavior: low
5 moisture content (3.72%) and redispersibility (8.6%) with a larger median particle size (6.5 μm). In addition, the product was crystalline (due to the presence of mannitol).

Stability

In all studies, the spray-dried powder products showed no
10 significant increase in deamidation. The stability in terms of changes in aggregation and enzymatic activity during storage at various temperatures is shown in the Tables 3-6. It is apparent that the sugars impart good long-term stability on rhDNase powders.

TABLE 3
Summary of Stability of rhDNase: Lactose Mixtures

Temp/Formulation	% Aggregation ¹			Activity of Methyl Green(S.A.) ³	
	3 months	6 months	3 months	3 months	6 months
@ 2-8°C 100% DNase 85.8% DNase 64.1% DNase 10.9% DNase	0.6	1.9	1.06	1.01	1.01
	0.0	0.7	1.06	1.01	1.01
	0.0	0.0	1.03	1.13	1.13
	0.2	6.2 ²	1.15	1.03	1.03
@ 25°C 100% DNase 85.8% DNase 64.1% DNase 10.9% DNase	1.9	2.9	0.98	0.87	0.87
	0.0	1.2	1.07	0.92	0.92
	0.2	0.4	1.07	1.00	1.00
	0.2	5.3 ²	1.15	1.05	1.05
@ 40°C 100% DNase 85.5% DNase 64.1% DNase 10.9% DNase	5.0	6.4	0.95	0.88	0.88
	1.0	5.9	0.94	0.85	0.85
	0.6	2.0	1.15	0.98	0.98
	0.7	5.0 ²	1.13	1.11	1.11

1. No data at time T = 0.
2. Possible clipping rather than aggregation.
3. Activity determined by methyl green assay normalized to the protein concentration measured by UV absorption.

TABLE 4
Summary of Stability of rhdNase Sugar Mixtures

Temp/Formulation	% Aggregation		Activity of Methyl Green (S.A.) ¹	
	0 months	10 months	0 months	10 months
@ 40°C				
35.4% DNase/70% Lactose	0.3	2.7	0.95	-
34.0% DNase/70% Mannitol	5.8	11.4	0.85	-
36.9% DNase/70% Sucrose	0.4	1.5	0.95	-
35.4% DNase/70% Trehalose	0.5	1.6	0.90	-

1. See footnote 3 in Table 3.

TABLE 5
Summary of Stability of rhdNase Sodium Chloride Mixtures

Temp/Formulation/Storage (1.2)	% Aggregation		Activity of Methyl Green (S.A.) ³	
	0 months	10 months	0 months	10 months
@ 40°C				
82.2% DNase	1.6	7.4	0.93	-
82.2% DNase (desiccator)	1.4	7.0	0.92	-
47.6% DNase	5.6	9.9	0.83	-
47.6% DNase (desiccator)	6.6	9.0	0.82	-
10.46% DNase	12.5	21.0	0.77	-
10.46% DNase (desiccator)	13.3	22.7	0.77	-

1. Ambient humidity storage.
2. Stored in sample tube in desiccator over calcium chloride.
3. See footnote 3 in Table 3.

TABLE 6
Summary of Stability of rhdNase Sodium Chloride 50:50* Mixtures

Temp/Liquid Concentration	% Aggregation		Activity of Methyl Green (S.A.) ²	
	0 months	4 months	0 months	4 months
@ 25°C				
1 mg/ml	9.9	2.7	0.85	-
15 mg/ml	6.2	8.8	0.87	-
38.4 mg/ml	4.4	9.1	0.92	-
Extra Ca ²⁺ (1)	4.8	9.1	0.86	-
@ 40°C				
1 mg/ml	9.9	21.1	0.85	-
15 mg/ml	6.2	16.0	0.87	-
38.4 mg/ml	4.4	15.5	0.92	-
Extra Ca ²⁺ (1)	4.8	15.0	0.86	-

1. Extra Ca²⁺ 1.9% of w. total.

2. See footnote 3 in Table 3.

* = Actual % rhdNase 47.6, NaCl 45.2.

-27-

References (Incorporated herein expressly by reference)

- Hatch, T. F. and Gross, P., Pulmonary Deposition and Retention of Inhaled Aerosol, Academic Press, New York, 1964.
- 5 Ganderton, D., The generation of respirable clouds from coarse powder aggregates, J. Biopharm. Sci. 3, 101-105 (1992).
- Masters, K., Spray Drying Handbook, 4th edition, Wiley & Sons, 1985.
- 10 Franks, F., Hatley, R. H. M. and Mathias, S. F., Materials science and the production of shelf-stable biologicals, BioPharm 4(9), 38-42 & 55 (1992).
- Bell, J. H., Hartley, P. S. and Cox, J. S. G., Dry powder aerosols I: a new powder inhalation device, J. Pharm. Sci. 60, 1559-1564 (1971).
- 15 Vidgren, M., Karkkainen, A., Karjalainen, P., Paronen, P. and Nuuyinen, J., Effect of powder inhaler design on drug deposition in the respiratory tract, Int. J. Pharm. 42, 211-216 (1988).
- 20 Kassem, N. M., Ho, K. K. L. and Ganderton, D., The effect of air flow and carrier size on the characteristics of an inspirable cloud, J. Pharm. Pharmacol. 41 (Suppl.) 14P (1989).
- 25 Kassem, N. M. and Ganderton, D., Influence of carrier surface on the characteristics of powder aerosols, J. Pharm. Pharmacol. 42 (Suppl.) 11P (1990).

Concluding Remarks

- The foregoing description details specific methods which can be employed to practice the present invention. Having
- 30 detailed specific methods used to prepare and characterize and therapeutically administer the formulation of DNase hereof, and further disclosure as to specific model systems pertaining thereto, those skilled in the art will well enough know how to devise alternative reliable
- 35 methods for arriving at the same information in using the fruits of the present invention. Thus, however detailed the foregoing may appear in text, it should not be construed as limiting the overall scope thereof; rather,

-28-

the ambit of the present invention is to be determined only by the lawful construction of the appended claims.



CLAIMS:

1. A method for the preparation of a pharmaceutically acceptable formulation comprising DNase which comprises:
 - a) spray-drying a liquid composition comprising a compatible excipient and DNase as active principle and
 - b) collecting the spray-dried product of step a) as a dispersible powder containing DNase in biologically active form.
2. The method according to Claim 1 wherein said spray-dried product is in the form of an aerosol suitable for administration via an aerosolization device into the lung of an individual.
3. The method according to Claim 1 wherein said spray-drying step is conducted at an inlet temperature such that formed droplets have a temperature not exceeding the denaturation temperature of DNase.
4. The method according to Claim 1 wherein said liquid composition has a concentration of DNase from about 1 to about 80 milligrams per milliliter.
5. The method according to Claim 1 wherein said DNase-containing powder contains less than about 4% of aggregated form of DNase.
6. The method according to Claim 1 wherein said liquid composition comprises NaCl as excipient in an amount of from about 10% to about 90% of the solids content.
7. The method according to Claim 1 wherein said liquid composition comprises sugar as excipient in an amount from about 10% to about 90% of the solids content.

-30-




8. The method according to Claim 1 including the step of dispersing said DNase-containing powder with an aerosolization device into the lung of an individual.
9. A pharmaceutically acceptable formulation comprising
5 DNase as active principle and a compatible excipient, as a product of spray-drying a corresponding liquid composition, said product containing DNase in biologically active form.
10. A pharmaceutically acceptable formulation according
10 to Claim 9 in aerosol form.
11. A pharmaceutically acceptable formulation according to Claim 9 wherein after recovering said spray-dried product said DNase is present therein in an amount of from about 0.01 to about 1 milligrams per milligram.

1 / 12



**FIG. 1****FIG. 17**

RECTIFIED SHEET (RULE 91)
ISA/EP



2 / 12

**FIG. 2A****FIG. 2B****FIG. 4**



RECTIFIED SHEET (RULE 91)
ISA/EP

**FIG._3****FIG._5**



4 / 12

**FIG. 6****FIG. 7**



5 / 12



6 / 12

**FIG. 9A****FIG. 9B**

RECTIFIED SHEET (RULE 91)
ISA/EP

**FIG. 13**

RECTIFIED SHEET (RULE 91)
ISA/EP

8/12

FIG._12A




FIG._12B





FIG._12C



9/12

FIG._12D




FIG._12E







FIG._12F





RECTIFIED SHEET (RULE 91)
ISA/EP

11/12

FIG._16A




FIG._16B





FIG._16C



RECTIFIED SHEET (RULE 91)

TSA/EP

12 / 12

FIG._16D




FIG._16E





FIG._16F



INTERNATIONAL SEARCH REPORT

Intern: 1 Application No

PCT/US 95/02041

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K38/46 C12N9/96 A61K9/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,90 07572 (GENENTECH INC) 12 July 1990 cited in the application see page 16, line 32 - page 17, line 6 ---	9-11
X	WO,A,93 25670 (GENENTECH INC.) 23 December 1993 cited in the application see page 6 ---	9-11
A	EP,A,0 501 375 (KAO CORPORATION) 2 September 1992 see the whole document ---	1-11
A	WO,A,91 18091 (QUADRANT HOLDINGS CAMBRIDGE LIMITED) 28 November 1991 see the whole document ---	1-11
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

24 May 1995

Date of mailing of the international search report

20. 06. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Fernandez y Branas, F

INTERNATIONAL SEARCH REPORT

Interr. al Application No
PCT/US 95/02041

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,4 233 405 (NEUBECK, C.E.) 11 November 1980 see the whole document ---	1-11
A	NETHERLANDS MILK AND DAIRY JOURNAL, vol. 23, 1969 DUIVENDAAL, NL, pages 46-54, M.J. VAN DE BEEK ET AL 'Preservation of the enzymatic activity of renin during spray drying and during storage, and the effect of sugars and certain other additives' see the whole document ---	1-11
A	S.T.P. PHARMACEUTICAL SCIENCES, vol. 4,no. 1, February 1994 PARIS, pages 50-62, CIPOLLA, D.C. ET AL 'Assessment of aerosol delivery systems for recombinant human deoxyribonuclease' see the whole document -----	1-11

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/02041

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 8 is directed to a method of treatment of the human/
animal body the search has been carried out and based on the alleged
effects of the composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No

PCT/US 95/02041

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9607572	12-07-90	AU-B- 630658	05-11-92
		AU-A- 4826590	01-08-90
		CA-A- 2006473	23-06-90
		EP-A- 0449968	09-10-91
		JP-T- 4502406	07-05-92

WO-A-9325670	23-12-93	US-A- 5279823	18-01-94
		AU-B- 4398193	04-01-94
		CA-A- 2137237	23-12-93
		EP-A- 0644932	29-03-95
		FI-A- 945549	25-11-94
		GB-A- 2282140	29-03-95
		NO-A- 944752	08-12-94

EP-A-501375	02-09-92	JP-A- 4271785	28-09-92

WO-A-9118091	28-11-91	AU-A- 7872591	10-12-91
		EP-A- 0541556	19-05-93
		JP-T- 5508315	25-11-93

US-A-4233405	11-11-80	NONE	

THIS PAGE BLANK (USPTO)